Rapport Therapeutics Q2 EPS $(1.19) Misses $(0.96) Estimate
Rapport Therapeutics (NASDAQ:RAPP) reported quarterly losses of $(1.19) per share which missed the analyst consensus estimate of $(0.96) by 23.96 percent. This is a 58.67 percent decrease over losses of $(0.75) per
Rapport Therapeutics lost more money per share than experts predicted, and its losses got worse compared to last year. When a company's losses grow bigger and miss expectations, it's a sign to watch whether their business is moving toward making money or getting further away.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.